During the past decade, Wasatch Pediatrics, Cottonwood Office conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 1 clinical trials were completed, i.e. on average, 25% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 1 clinical trials were completed. i.e. 33.3% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Wasatch Pediatrics, Cottonwood Office" are "Pneumococcal Disease" (2 trials), "Influenza" (1 trials), "Meningococcal Infections" (1 trials), "Meningococcal Vaccine" (1 trials) and "Pneumococcal Infections" (1 trials). Many other conditions were trialed in "Wasatch Pediatrics, Cottonwood Office" in a lesser frequency.

Most popular intervention types in "Wasatch Pediatrics, Cottonwood Office" are "Biological" (5 trials) and "Drug" (1 trials). Other intervention types were less common.

The name of intervention was led by "13-valent pneumococcal conjugate vaccine" (1 trials), "13vPnC" (1 trials), "20-valent pneumococcal conjugate vaccine" (1 trials), "20vPnC" (1 trials) and "Licensed meningococcal ACWY vaccine" (1 trials). Other intervention names were less common.

The vast majority of trials in "Wasatch Pediatrics, Cottonwood Office" are 6 trials for "All" genders.

Currently, there are NaN active trials in "Wasatch Pediatrics, Cottonwood Office". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Wasatch Pediatrics, Cottonwood Office, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Wasatch Pediatrics, Cottonwood Office, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".